An update on drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors

Introduction: Carbonic anhydrase inhibitors (CAIs) have been in clinical use for decades for the management of various disorders. An update on their drug–drug interactions is presented here considering these main therapeutic areas and drugs: glaucoma (acetazolamide, methazolamide, dichlorophenamide, dorzolamide, and brinzolamide); epilepsy/obesity (sulthiame, topiramate, and zonisamide); arthritis/inflammation (celecoxib and polmacoxib) and...